

What is claimed is:

Sub C1

1. A ligand-bonded complex in which a microparticle is directly or indirectly bonded to a ligand having affinity for a target substance, wherein the affinity of the ligand is sufficient to allow substantially specific binding of the ligand-bonded complex to a non-free target even in the presence of a free target.

2. The ligand-bonded complex according to claim 1, wherein two or more molecules of a single kind of the ligand having substantially the same affinity are bonded to one microparticle.

3. The ligand-bonded complex according to claim 2, wherein an amount of the ligand is sufficient for reaction with the non-free target.

4. The ligand-bonded complex according to any one of claims 1 to 3, wherein the ligand is directly bonded to the microparticle.

5. The ligand-bonded complex according to any one of claims 1 to 4, wherein a water-soluble macromolecule is bonded to the microparticle.

6. The ligand-bonded complex according to any one of claims 1 to 5, wherein a part of or all of the ligand molecules are indirectly bonded to the microparticle by means of a water-soluble macromolecule.

7. The ligand-bonded complex according to claim 5 or claim 6, wherein the water-soluble macromolecule is a polyalkylene glycol.

8. The ligand-bonded complex according to claim 5 or claim 6, wherein the water-soluble macromolecule is polyethylene glycol.

9. The ligand-bonded complex according to any one of claims 1 to 8, wherein the microparticle is selected from the group consisting of a low molecular drug, a marker molecule, a protein, a micelle, and a liposome.

10. The ligand-bonded complex according to claim 9, wherein the microparticle is a liposome.

11. The ligand-bonded complex according to claim 10, wherein the liposome encapsulates an active principle of a medicament.

12. The ligand-bonded complex according to claim 11, wherein the medicament is an anti-tumor agent.

13. The ligand-bonded complex according to any one of claims 1 to 12, wherein

Sub
A24m initiated
the ligand is an antibody.

14. The ligand-bonded complex according to claim 13, wherein the antibody is an anti-tumor antibody.

Sub
C4
15. The ligand-bonded complex according to claim 14, wherein the antibody is bonded by means of a wafer-soluble macromolecule to a liposome encapsulating an anti-tumor agent.

Sub
C5
Sub
A3
16. The ligand-bonded complex according to any one of claims 1 to 15, wherein dissociation constant between the target and one ligand is $E-8$ M or more.

17. The ligand-bonded complex according to any one of claims 1 to 15, wherein dissociation constant between the target and one ligand is $E-7$ M or more.

18. A pharmaceutical composition comprising a ligand-bonded complex according to any one of claims 1 to 17.

Sub
C5
Sub
A3
"45T" 122601
Add
D2